Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Poster session will highlight potential of ZL-1218 to modulate tumor microenvironment and regulate anticancer immune response i...
Cantor Fitzgerald analyst Louise Chen reiterates Zai Lab (NASDAQ:ZLAB) with a Overweight.
Zai Lab (NASDAQ:ZLAB) reported quarterly losses of $(0.82) per ADS which missed the analyst consensus estimate of $(0.70) by 17...
First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients i...
Manuscript represents the first publication from China's gynecology oncology field to be published in CellPublication highl...
JP Morgan analyst Anupam Rama maintains Zai Lab (NASDAQ:ZLAB) with a Overweight and lowers the price target from $43 to $38.
Cantor Fitzgerald analyst Louise Chen reiterates Zai Lab (NASDAQ:ZLAB) with a Overweight.
